Spots Global Cancer Trial Database for Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery

Official Title: A Phase 2 Study of GTX-SRS: Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery for Borderline Resectable Pancreatic Cancer

Study ID: NCT00833859

Conditions

Pancreatic Neoplasms

Interventions

GTX (gemcitabine, docetaxel and capecitabine)

stereotactic body radiation therapy

Study Description

Brief Summary: The purpose of this study is to find out if a program of intensive chemotherapy with gemcitabine, docetaxel and capecitabine followed by an advanced form of focused radiation aimed at the patient's tumor followed by more chemotherapy can increase the chances that the patient's pancreatic tumor can be removed completely.

Detailed Description: * Cycle 1 and 2: * Days 4, 11 and 25, 32 ....gemcitabine 750 mg/m\^2 intravenous piggy back (IVPB) over 30 min * Days 4, 11 and 25, 32 ....docetaxel 30 mg/m\^2 IVPB over 1 hour * Days 1-14 and 22-35 ....capecitabine 750 mg/m\^2 oral twice daily * Each cycle is 21 days long * SRS: Day 43 ....25 Gy single fraction to the pancreatic tumor gross target volume * Cycle 3 and 4: * Days 54, 61 and 75, 82 ....gemcitabine 750 mg/m\^2 IVPB over 30 min * Days 54, 61 and 75, 82 ....docetaxel 30 mg/m\^2 IVPB over 1 hour * Days 51-64 ....capecitabine 750 mg/m\^2 oral twice daily * Each cycle is 21 days long * Surgery: Exploratory laparotomy or laparoscopy followed by pancreaticoduodenectomy or central pancreatectomy with or without vein resection and reconstruction as appropriate.